Daily Bulletin

Business Mentor

.

Cipla and Stempeutics collaborate for launch of Stempeucel®, first 'Made in India' Cell Therapy to treat Critical Limb Ischemia (CLI)

  • Written by PR Newswire Asia - Daily Bulletin Au RSS

- First approved allogeneic cell therapy product globally for the treatment of CLI

- Developed by Stempeutics over a period of twelve years, breakthrough treatment designed to address root cause of the disease at an affordable cost

- Cipla to market and distribute the drug in India to provide patient access

Cipla and Stempeutics collaborate for launch of Stempeucel®, first 'Made in India' Cell Therapy to treat Critical Limb Ischemia (CLI)

MUMBAI, India, Aug. 21, 2020 /PRNewswire/...

Read more: Cipla and Stempeutics collaborate for launch of Stempeucel®, first 'Made in India' Cell Therapy to...

Business News

How to Ensure Effective and Long-Lasting Concrete Repair:

Most minor concrete works can be done quickly and simply by hand. Concrete surfaces can be found in a variety of places not just for their strength but also for their ease of use. Concrete must with...

Daily Bulletin - avatar Daily Bulletin

Precision Matters: Builders Takeoff for Accurate Estimates

With this in mind, accurate estimates are not just a critical but a fundamental part of Builders Takeoff to enable success. Every aspect matters in this volatile sector where no project is alike. A ...

Daily Bulletin - avatar Daily Bulletin

Cable Management & The Benefits That It Can Present For Your Australian Business

We very much rely on technology to drive our businesses forward here in Australia and if you are a business owner then you certainly will not be the exception. It would be impossible for any busines...

Daily Bulletin - avatar Daily Bulletin

Tomorrow Business Growth